Bridging the divide between discovery and delivering patient-specific medicines is the goal of many biotech companies. Our unique approach utilises Tay Therapeutics’ technology platform coupled to in-house discovery and development expertise to deliver substantial improvements in patient care.

Squiggle Graphic
LATEST NEWS
June 13, 2024
VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202
June 5, 2024
VYNE Therapeutics Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201
May 6, 2024
VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor